Iron Sucrose

IV Incompatibilities

Do not mix with other medications or add to parenteral nutrition solutions for IV infusion

IV Compatibilities

Solution: 0.9% NaCl

IV Administration

HD-dependent CKD

• May be administered via dialysis line as the undiluted solution or by diluting 100 mg (5 mL) in 100 mL 0.9% NaCl
• Administer either by slow IV injection over 2-5 min or IV infusion over at least 15 min

Non-dialysis-dependent CKD

• Administer undiluted by slow IV inj over 2-5 min

PD-dependent CKD

• Dilute dose in a maximum of 250 mL 0.9% NaCl
• 300 mg doses: infuse IV over 1.5 hr
• 400 mg dose: infuse IV over 2.5 hr

Pediatric

• Undiluted: Administer by slow IV injection over 5 minutes
• Diluted in 25 mL of 0.9% NaCl: Administer IV over 5-60 minutes

Storage

Store vials at room temp; do not freeze

Storage

Parenteral

20–25°C (may be exposed to 15–30°C); do not freeze.1

When diluted with 0.9% sodium chloride injection at concentrations of 2–10 mg of elemental iron per mL and stored in a plastic syringe, stable for 7 days at controlled room temperature (25 ± 2°C) or under refrigeration (4 ± 2°C).1

When stored undiluted in a plastic syringe at a concentration of 20 mg of elemental iron per mL, stable for 7 days at 25 ± 2°C or 4 ± 2°C.1

When added to IV infusion bags containing 0.9% sodium chloride injection at concentrations of 1–2 mg of elemental iron per mL, stable for 7 days at 25 ± 2°C.1

Contains no preservatives; use immediately after opening vial(s).1

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Iron sucrose injection should not be mixed with other drugs or added to parenteral nutrition solutions for IV infusion.1

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

• If you have an allergy to iron sucrose or any other part of iron sucrose.
• If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
• If you have any of these health problems: Anemia from a cause other than low iron stores or too much iron in your body.

This is not a list of all drugs or health problems that interact with this medicine.

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take iron sucrose with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
• Chest pain or pressure.
• Very bad dizziness or passing out.
• Very bad headache.
• Shortness of breath.
• Swelling in the arms or legs.
• Irritation where the shot is given.

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

• Iron (III) Hydroxide Sucrose Complex
• Iron sucrose complex, inj

Store intact vials at controlled room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze. Iron sucrose is stable for 7 days at room temperature (23°C to 27°C [73°F to 81°F]) or under refrigeration (2°C to 6°C [36°F to 43°F]) when undiluted in a plastic syringe or following dilution in normal saline in a plastic syringe (concentration 2-10 mg/mL) or for 7 days at room temperature (23°C to 27°C [73°F to 81°F]) following dilution in normal saline in an IV bag (concentration 1-2 mg/mL).

Concerns related to adverse effects:

• Hypersensitivity reactions: Cases of hypersensitivity reactions, including rare postmarketing anaphylactic and anaphylactoid reactions (some fatal), have been reported. Monitor patients during and for ≥30 minutes postadministration; discontinue immediately for signs/symptoms of a hypersensitivity reaction (shock, hypotension, loss of consciousness). Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.

• Hypotension: Significant hypotension has been reported frequently in hemodialysis-dependent patients. Has also been reported in peritoneal dialysis and nondialysis patients. Hypotension may be related to total dose or rate of administration (avoid rapid IV injection), follow recommended guidelines.

Other warnings/precautions:

• Appropriate use: Withhold iron in the presence of tissue iron overload; periodic monitoring of hemoglobin, hematocrit, serum ferritin, and transferrin saturation is recommended.